Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

References

• Avonex (interferon beta-1a) [package insert]. Cambridge, MA: Biogen Idec, Inc.; 20051Avonex (interferon beta-1a) [package insert]. Cambridge, MA: Biogen Idec, Inc.; 2005
   Google Scholar
• Betaseron (interferon beta-1b) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals2Betaseron (interferon beta-1b) [package insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals
   Google Scholar
• Rebif (interferon beta-1a) [package insert]. Rockland, MA: Serono, Inc.; 20053Rebif (interferon beta-1a) [package insert]. Rockland, MA: Serono, Inc.; 2005
   Google Scholar
• Copaxone (glatiramer acetate injection) [package insert]. Kansas City, MO: Teva Pharmaceutical Industries, Inc.; 20044Copaxone (glatiramer acetate injection) [package insert]. Kansas City, MO: Teva Pharmaceutical Industries, Inc.; 2004
   Google Scholar
• Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec Inc.; 20085Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec Inc.; 2008
   Google Scholar
• Solu-Medrol (methylprednisolone sodium succinate) [package insert]. New York, NY: Pharmacia & Upjohn Company; 20066Solu-Medrol (methylprednisolone sodium succinate) [package insert]. New York, NY: Pharmacia & Upjohn Company; 2006
   Google Scholar
• Frohman E, Phillips T, Kokel K. et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227–367Frohman E, Phillips T, Kokel K. et al. Disease-modifying therapy in multiple sclerosis: strategies for optimizing management. Neurologist 2002;8:227–36
   PubMed Web of Science ®Google Scholar
• Munschauer FE 3rd, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883–938Munschauer FE 3rd, Kinkel RP. Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis. Clin Ther 1997;19:883–93
   PubMed Web of Science ®Google Scholar
• Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000; 22:149–599Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Safety 2000; 22:149–59
   PubMed Web of Science ®Google Scholar
• Lublin FD, Whitaker JN, Eidelman BH. et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12–1810Lublin FD, Whitaker JN, Eidelman BH. et al. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology 1996;46:12–18
   PubMed Web of Science ®Google Scholar
• Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622–711Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999;53:1622–7
   PubMed Web of Science ®Google Scholar
• Reese J, Haas J, Gabriel K. et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler 2002;8:15–1812Reese J, Haas J, Gabriel K. et al. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX®) therapy. Mult Scler 2002;8:15–18
   PubMed Web of Science ®Google Scholar
• Brandes DW, Bigley K, Hornstein W. et al. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. Curr Med Res Opin 2007;23:1667–7213Brandes DW, Bigley K, Hornstein W. et al. Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study. Curr Med Res Opin 2007;23:1667–72
   PubMed Web of Science ®Google Scholar
• Río J, Nos C, Marzo ME. et al. Low-dose steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998;50:1910–1214Río J, Nos C, Marzo ME. et al. Low-dose steroids reduce flu-like symptoms at the initiation of IFNβ-1b in relapsing-remitting MS. Neurology 1998;50:1910–12
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Weber F, Gunther A. et al. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis. Neurology 1996;47:60415Rieckmann P, Weber F, Gunther A. et al. The phosphodiesterase inhibitor pentoxifylline reduces early side effects of interferon-beta 1b treatment in patients with multiple sclerosis. Neurology 1996;47:604
   PubMed Web of Science ®Google Scholar
• Gaines AR, Varricchio F. Interferon beta-1b injection site reactions and necroses. Mult Scler 1998;4:70–316Gaines AR, Varricchio F. Interferon beta-1b injection site reactions and necroses. Mult Scler 1998;4:70–3
   PubMed Web of Science ®Google Scholar
• Cohen BA, Greenberger PA, Saini S. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. Allergy Asthma Proc 1998; 19:85–817Cohen BA, Greenberger PA, Saini S. Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. Allergy Asthma Proc 1998; 19:85–8
   PubMed Web of Science ®Google Scholar
• Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002;58(Suppl 4):S10–2218Calabresi PA. Considerations in the treatment of relapsing-remitting multiple sclerosis. Neurology 2002;58(Suppl 4):S10–22
   PubMed Web of Science ®Google Scholar
• Klapper JA. Interferon beta treatment of multiple sclerosis. Neurology 1994; 44:188A19Klapper JA. Interferon beta treatment of multiple sclerosis. Neurology 1994; 44:188A
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA. et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–9420Jacobs LD, Cookfair DL, Rudick RA. et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285–94
   PubMed Web of Science ®Google Scholar
• PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-50421PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-722European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7
   PubMed Web of Science ®Google Scholar
• Patten SB, Metz LM. Interferon β-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001;7:243–823Patten SB, Metz LM. Interferon β-1a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler 2001;7:243–8
   PubMed Web of Science ®Google Scholar
• Patten SB, Metz LM. Interferon β-1a and depression in secondary progressive MS: data from the SPECTRIMS trial. Neurology 2002;59:744–624Patten SB, Metz LM. Interferon β-1a and depression in secondary progressive MS: data from the SPECTRIMS trial. Neurology 2002;59:744–6
   PubMed Web of Science ®Google Scholar
• Patten SB, Fridhandler S, Beck CA. et al. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003;9: 616–2025Patten SB, Fridhandler S, Beck CA. et al. Depressive symptoms in a treated multiple sclerosis cohort. Mult Scler 2003;9: 616–20
   PubMed Web of Science ®Google Scholar
• Patten SB, Beck CA, Williams JV. et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003;61:1524–726Patten SB, Beck CA, Williams JV. et al. Major depression in multiple sclerosis: a population-based perspective. Neurology 2003;61:1524–7
   PubMed Web of Science ®Google Scholar
• Mohr DC, Goodkin DE, Likosky W. et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531–327Mohr DC, Goodkin DE, Likosky W. et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol 1997;54:531–3
   PubMed Web of Science ®Google Scholar
• The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-6128The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Tremlett H, Porciuncula J, Yoshida E. et al. Post-marketing surveillance: Liver test abnormalities during treatment with interferon b -1a(sc), -1a(im) and -1b(sc) in clinical practice. Neurology 2003;60(Suppl 1):A5529Tremlett H, Porciuncula J, Yoshida E. et al. Post-marketing surveillance: Liver test abnormalities during treatment with interferon b -1a(sc), -1a(im) and -1b(sc) in clinical practice. Neurology 2003;60(Suppl 1):A55
   Google Scholar
• Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 2004;251: 1297–30330Tremlett H, Oger J. Hepatic injury, liver monitoring and the beta-interferons for multiple sclerosis. J Neurol 2004;251: 1297–303
   PubMed Web of Science ®Google Scholar
• Novantrone (mitoxantrone) for injection concentrate [package insert]. Rockland, MA: Serono Inc.; 200531Novantrone (mitoxantrone) for injection concentrate [package insert]. Rockland, MA: Serono Inc.; 2005
   Google Scholar
• Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997;54:1169–9032Schwid SR, Goodman AD, Mattson DH. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b. Arch Neurol 1997;54:1169–90
   PubMed Web of Science ®Google Scholar
• Durelli L, Bongioanni MR, Ferrero B. et al. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998;50:570–133Durelli L, Bongioanni MR, Ferrero B. et al. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998;50:570–1
   PubMed Web of Science ®Google Scholar
• Rotondi M, Oliviero A, Profice P. et al. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 1998;21:748–5234Rotondi M, Oliviero A, Profice P. et al. Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 1998;21:748–52
   PubMed Web of Science ®Google Scholar
• Durelli L, Ferrero B, Oggero A. et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999;162:74–8335Durelli L, Ferrero B, Oggero A. et al. Autoimmune events during interferon beta-1b treatment for multiple sclerosis. J Neurol Sci 1999;162:74–83
   PubMed Web of Science ®Google Scholar
• Durelli L, Ferrero B, Oggero A. et al. Liver and thyroid function and autoimmunity during interferon-β-1b treatment for MS. Neurology 2001;57:1363–7036Durelli L, Ferrero B, Oggero A. et al. Liver and thyroid function and autoimmunity during interferon-β-1b treatment for MS. Neurology 2001;57:1363–70
   PubMed Web of Science ®Google Scholar
• Kreisler A, de Seze J, Stojkovic T. et al. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand 2003;107:154–737Kreisler A, de Seze J, Stojkovic T. et al. Multiple sclerosis, interferon beta and clinical thyroid dysfunction. Acta Neurol Scand 2003;107:154–7
   PubMed Web of Science ®Google Scholar
• Caraccio N, Dardano A, Manfredonia F. et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-β-1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005;90:4133–738Caraccio N, Dardano A, Manfredonia F. et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-β-1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005;90:4133–7
   PubMed Web of Science ®Google Scholar
• Sandberg-Wollheim M, Frank D, Goodwin TM. et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005;65:802–639Sandberg-Wollheim M, Frank D, Goodwin TM. et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 2005;65:802–6
   PubMed Web of Science ®Google Scholar
• Boskovic R, Wide R, Wolpin J. et al. The reproductive effects of beta interferon therapy in pregnancy. A longitudinal cohort. Neurology 2005;65:807–1140Boskovic R, Wide R, Wolpin J. et al. The reproductive effects of beta interferon therapy in pregnancy. A longitudinal cohort. Neurology 2005;65:807–11
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004;63(Suppl 5):S35–4141Langer-Gould A, Moses HH, Murray TJ. Strategies for managing the side effects of treatments for multiple sclerosis. Neurology 2004;63(Suppl 5):S35–41
   PubMed Web of Science ®Google Scholar
• Blake G, Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon beta-1b treatment. Neurology 1997;49:1747–842Blake G, Murphy S. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon beta-1b treatment. Neurology 1997;49:1747–8
   PubMed Web of Science ®Google Scholar
• Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol 1998;39:1024–843Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol 1998;39:1024–8
   PubMed Web of Science ®Google Scholar
• Ubara Y, Hara S, Takedatu H. et al. Hemolytic uremic syndrome associated with β-interferon therapy for chronic hepatitis C. Nephron 1998;80:107–844Ubara Y, Hara S, Takedatu H. et al. Hemolytic uremic syndrome associated with β-interferon therapy for chronic hepatitis C. Nephron 1998;80:107–8
   PubMed Web of Science ®Google Scholar
• Schmidt S, Hertfelder HJ, von Spiegel T. et al. Lethal capillary leak syndrome after a single administration of interferon beta 1-b. Neurology 1999;53:220–245Schmidt S, Hertfelder HJ, von Spiegel T. et al. Lethal capillary leak syndrome after a single administration of interferon beta 1-b. Neurology 1999;53:220–2
   PubMed Web of Science ®Google Scholar
• Herrera WG, Balizet LB, Harberts SW. et al. Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis. Neurology 1999;52:A13546Herrera WG, Balizet LB, Harberts SW. et al. Occurrence of a TTP-like syndrome in two women receiving beta interferon therapy for relapsing multiple sclerosis. Neurology 1999;52:A135
   Web of Science ®Google Scholar
• Corona T, Leon C, Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology 1999;52:42547Corona T, Leon C, Ostrosky-Zeichner L. Severe anaphylaxis with recombinant interferon beta. Neurology 1999;52:425
   PubMed Web of Science ®Google Scholar
• Webster GF, Knobler RL, Lublin FD. et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996;34:365–748Webster GF, Knobler RL, Lublin FD. et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996;34:365–7
   PubMed Web of Science ®Google Scholar
• Kanda Y, Shigeno K, Matsuo H. et al. Interferon-induced sudden hearing loss. Audiology 1995;34:98–10249Kanda Y, Shigeno K, Matsuo H. et al. Interferon-induced sudden hearing loss. Audiology 1995;34:98–102
   PubMedGoogle Scholar
• Edgar CM, Brunet DG, Fenton P. et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58–6350Edgar CM, Brunet DG, Fenton P. et al. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci 2004;31:58–63
   PubMed Web of Science ®Google Scholar
• Goodin DS, Arnason BG, Coyle PK. et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Neurology 2003;61:1332–851Goodin DS, Arnason BG, Coyle PK. et al. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Neurology 2003;61:1332–8
   PubMed Web of Science ®Google Scholar
• Strotmann JM, Spindler M, Weilbach FX. et al. Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Am J Cardiol 2002;89:1222–552Strotmann JM, Spindler M, Weilbach FX. et al. Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Am J Cardiol 2002;89:1222–5
   PubMed Web of Science ®Google Scholar
• Ghalie RG, Edan G, Laurent M. et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909–1353Ghalie RG, Edan G, Laurent M. et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909–13
   PubMed Web of Science ®Google Scholar
• Hartung H-P, Gonsette R, König N. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018–2554Hartung H-P, Gonsette R, König N. et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018–25
   PubMed Web of Science ®Google Scholar
• DeCastro S, Cartoni D, Millefiorini E. et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995;35:627–3255DeCastro S, Cartoni D, Millefiorini E. et al. Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995;35:627–32
   PubMed Web of Science ®Google Scholar
• Ghalie RG, Mauch E, Edan G. et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441–556Ghalie RG, Mauch E, Edan G. et al. A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441–5
   PubMed Web of Science ®Google Scholar
• Voltz R, Starck M, Zingler V. et al. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler. 2004;10:472–457Voltz R, Starck M, Zingler V. et al. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler. 2004;10:472–4
   PubMed Web of Science ®Google Scholar
• Brassat D, Recher C, Waubant E. et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59:954–558Brassat D, Recher C, Waubant E. et al. Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology 2002;59:954–5
   PubMed Web of Science ®Google Scholar
• Arruda WO, Montu MB, de Oliveira Mde S. et al. Acute myeloid leukaemia induced by mitoxantrone: case report. Arq Neuropsiquiatr 2005;63(2A):327–959Arruda WO, Montu MB, de Oliveira Mde S. et al. Acute myeloid leukaemia induced by mitoxantrone: case report. Arq Neuropsiquiatr 2005;63(2A):327–9
   PubMed Web of Science ®Google Scholar
• Cocco E, Marchi P, Sardu C, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007;13:975-8060Cocco E, Marchi P, Sardu C, et al. Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis. Mult Scler 2007;13:975-80
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–91061Polman CH, O’Connor PW, Havrdova E. et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910
   PubMed Web of Science ®Google Scholar
• Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369–7462Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369–74
   PubMed Web of Science ®Google Scholar
• Langer-Gould A, Atlas SW, Green AJ. et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375–8163Langer-Gould A, Atlas SW, Green AJ. et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005;353:375–81
   PubMed Web of Science ®Google Scholar
• Van Assche G, Van Ranst M, Sciot R. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362–864Van Assche G, Van Ranst M, Sciot R. et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362–8
   PubMed Web of Science ®Google Scholar
• Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005; 353:432–365Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005; 353:432–3
   PubMed Web of Science ®Google Scholar
• Yousry TA, Major EO, Ryschkewitsch C. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924–3366Yousry TA, Major EO, Ryschkewitsch C. et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354:924–33
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Hartung H-P. et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431–4167Kappos L, Bates D, Hartung H-P. et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431–41
   PubMed Web of Science ®Google Scholar
• Mattson DH. Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the ‘ABCNR’ drugs in multiple sclerosis. Semin Neurol 2002; 22:17–2568Mattson DH. Alphabet soup: a personal, evolving, mostly evidence-based and logical, sequential approach to the ‘ABCNR’ drugs in multiple sclerosis. Semin Neurol 2002; 22:17–25
   PubMed Web of Science ®Google Scholar
• Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511–669Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high-dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511–6
   PubMed Web of Science ®Google Scholar
• Barnes MP, Bateman DE, Cleland PG. et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985;48:157–970Barnes MP, Bateman DE, Cleland PG. et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985;48:157–9
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Kinkel RP, Weinstock-Guttman B. et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998;51:239–4571Goodkin DE, Kinkel RP, Weinstock-Guttman B. et al. A phase II study of IV methylprednisolone in secondary-progressive multiple sclerosis. Neurology 1998;51:239–45
   PubMed Web of Science ®Google Scholar
• Zivadinov R, Rudick RA, De Masi R. et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–4772Zivadinov R, Rudick RA, De Masi R. et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–47
   PubMed Web of Science ®Google Scholar
• Zorzon M, Zivadinov R, Locatelli L. et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005;12:550–673Zorzon M, Zivadinov R, Locatelli L. et al. Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis. Eur J Neurol 2005;12:550–6
   PubMed Web of Science ®Google Scholar
• Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289–9474Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol 2001;33:289–94
   PubMed Web of Science ®Google Scholar
• Then Bergh F, Kümpfel T, Schumann E. et al. Monthly intravenous methylprednisolone in relapsing multiple sclerosis – reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 2006;6:1975Then Bergh F, Kümpfel T, Schumann E. et al. Monthly intravenous methylprednisolone in relapsing multiple sclerosis – reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. BMC Neurol 2006;6:19
   PubMed Web of Science ®Google Scholar
• Nesbitt LT Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin 1995;13:925–3976Nesbitt LT Jr. Minimizing complications from systemic glucocorticosteroid use. Dermatol Clin 1995;13:925–39
   PubMed Web of Science ®Google Scholar
• Burgdorff T, Venemalm L, Vogt T. et al. IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. Ann Allergy Asthma Immunol 2002;89:425–877Burgdorff T, Venemalm L, Vogt T. et al. IgE-mediated anaphylactic reaction induced by succinate ester of methylprednisolone. Ann Allergy Asthma Immunol 2002;89:425–8
   PubMed Web of Science ®Google Scholar
• Akikusa JD, Feldman BM, Gross GJ. et al. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics 2007; 119:e778–8278Akikusa JD, Feldman BM, Gross GJ. et al. Sinus bradycardia after intravenous pulse methylprednisolone. Pediatrics 2007; 119:e778–82
   PubMed Web of Science ®Google Scholar
• Kumari R, Uppal SS. First report of supraventricular tachycardia after intravenous pulse methylprednisolone therapy, with a brief review of the literature. Rheumatol Int 2005;26:70–379Kumari R, Uppal SS. First report of supraventricular tachycardia after intravenous pulse methylprednisolone therapy, with a brief review of the literature. Rheumatol Int 2005;26:70–3
   PubMed Web of Science ®Google Scholar
• Osgocmen S, Bulut S, Ilhan N. et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Min Metab 2005;23:309–1380Osgocmen S, Bulut S, Ilhan N. et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Min Metab 2005;23:309–13
   PubMed Web of Science ®Google Scholar
• Weinstock-Guttman B, Gallagher E, Baier M. et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004; 10:170–581Weinstock-Guttman B, Gallagher E, Baier M. et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004; 10:170–5
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 update. Arthritis Rheum 2001;44: 1496-150382American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 update. Arthritis Rheum 2001;44: 1496-1503
   PubMed Web of Science ®Google Scholar
• Newman ED, Matzko CK, Olenginski TP. et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006;17:1428–3483Newman ED, Matzko CK, Olenginski TP. et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006;17:1428–34
   PubMed Web of Science ®Google Scholar
• Ringe JD, Farahmand P. Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clin Rheumatol 2007;26:474–8484Ringe JD, Farahmand P. Advances in the management of corticosteroid-induced osteoporosis with bisphosphonates. Clin Rheumatol 2007;26:474–84
   PubMed Web of Science ®Google Scholar